When to Sunset and When to Scale: A Strategic Checklist for Tail-End Brands

Deciding whether to sunset or scale tail-end brands—generics or OTC products with declining sales—is a critical challenge for pharma companies. In India’s Tier 2/3 markets, where generics drive 60% of prescriptions (IQVIA, 2025), these brands often hold untapped potential. For Medstry’s clients—small to mid-sized pharma, OTC, and healthcare providers—strategic decisions can unlock millions in revenue while aligning with India’s affordable healthcare goals. This checklist provides a framework to evaluate tail-end brands, ensuring firms scale winners and sunset true losers.

The Opportunity: Smarter Portfolio Decisions

India’s Tier 2/3 markets, with 70% of the population, are projected to drive 60% of healthcare spending growth by 2030 (Deloitte, 2025). Tail-end brands, especially generics for chronic conditions like diabetes (20% rural prescriptions, Lancet, 2025), can thrive here. A 2024 McKinsey study found 40% of delisted generics could have yielded 12% ROI with rural repositioning. By auditing portfolios, engaging stakeholders, and leveraging cost-effective channels, firms can make data-driven decisions to scale viable brands and sunset those with no future, gaining an edge over regional competitors (20% share gain in 2024, BCG, 2025).

Strategic Checklist for Decision-Making

1. Analyze Sales and Prescription Data

   Use AI-driven analytics to identify tail-end brands with steady demand in Tier 3 towns, focusing on generics for high-prevalence conditions (50% rural prevalence, IQVIA, 2025). Cross-reference with DPCO-listed drugs to assess regulatory viability, cutting analysis costs by 25% (ZS, 2025).

   
   

2. Evaluate Chemist Influence

   Assess chemist uptake, as they drive 65% of rural prescriptions (IMS Health, 2025). Brands with low chemist engagement may warrant sunsetting unless training can boost sales by 15% (IMS Health, 2024).

   
   

3. Assess Micro-Market Potential

   Map sales to Tier 2/3 regions, where 40% of generics show consistent demand (IQVIA, 2025). Brands with no regional traction may be candidates for retirement.

   
   

4. Reposition for Rural Viability

   Test vernacular messaging and smaller pack sizes to align with rural budgets, increasing uptake by 18% (Deloitte, 2024). Brands unresponsive to repositioning may be sunsetted.

   
   

5. Launch Pilot Digital Campaigns

   Deploy SMS or WhatsApp campaigns in regional languages, reaching 85% of rural smartphone users (TRAI, 2025). If pilots drive 20% adherence (BCG, 2024), scale; if not, consider retirement.

   
   

6. Optimize Supply Chain Feasibility

   Partner with micro-warehouses to reduce stockouts by 20%, ensuring 90% availability (McKinsey, 2024). Brands with persistent logistics issues may not justify scaling.

   
   

7. Align with Regulatory Frameworks

   Ensure DPCO compliance and PM-JAY eligibility, increasing reach by 12% (NPPA, 2025). Non-compliant brands with low demand may be sunsetted.

   
   

8. Monitor KPIs for Scalability

   Track prescription share, chemist uptake, and patient retention with digital dashboards, targeting 10% quarterly growth (PwC, 2025). Brands failing to hit 5% growth after pilots may warrant retirement.

The Impact: Optimized Portfolios, High ROI

This checklist costs $1–2 million to implement, delivering 12–15% ROI within 18 months for scaled brands (McKinsey, 2025). Impacts include:

• Revenue Growth: Scaled generics yield 10–15% margins in Tier 3 markets (IQVIA, 2025).

• Resource Efficiency: Sunsetting unviable brands frees 20% of marketing budgets (ZS, 2025).

• Market Share: Strategic scaling prevents 18% share loss to regional players (BCG, 2025).

• Health Equity: Affordable generics improve adherence by 30%, aligning with Medstry’s mission (WHO, 2025).

Firms enhance portfolio efficiency, boost CSR credentials, and position themselves as leaders in underserved markets.

Addressing Decision Risks

• Data Gaps: Use AI analytics to ensure robust insights, reducing errors by 30% (BCG, 2024).

• Stakeholder Resistance: Pilot in 5–10 Tier 3 towns to build buy-in with 10% growth data (BCG, 2024).

• Competitive Pressure: Target niche conditions like asthma (30% less competition, Lancet, 2025).

• Regulatory Uncertainty: Focus on DPCO-compliant brands to mitigate risks (NPPA, 2025).

Why 2025 Is Critical

With Ayushman Bharat expanding to 500 million rural patients (NPPA, 2025) and regional players gaining 20% share in Tier 3 markets (BCG, 2025), 2025 is a pivotal year to optimize tail-end brands.

Partner with Medstry to Revive Your Brands

At Medstry Biotech, we help pharma clients decide when to scale tail-end brands in Tier 2/3 markets. Our strategic expertise drives growth. Contact us at contact@medstry.in to learn more.

The Bottom Line

Tail-end brands require smart decisions to scale or sunset. Medstry’s checklist empowers clients to optimize portfolios, drive revenue, and advance healthcare access in India’s Tier 2/3 markets in 2025.